| Original language | English (US) |
|---|---|
| Pages (from-to) | 1018-1026 |
| Number of pages | 9 |
| Journal | JAAD Case Reports |
| Volume | 5 |
| Issue number | 12 |
| DOIs | |
| State | Published - Dec 2019 |
Funding
Conflicts of Interest: Dr Damsky has research funding from Pfizer and is a consultant for Eli Lilly. Dr Vesely's spouse works at Regeneron. Dr Choi has served on advisory boards for Merck, Pfizer, and EMD Serono. This article was prepared while Dr Meyer was employed by Yale University. The opinions expressed in this article are Dr Meyer's own and do not reflect the views of the US Army Medical Research and Material Command, the Department of the Army, the Department of Defense, or the United States Government. Dr King an investigator for Concert Pharmaceuticals Inc, Eli Lilly and Company, and Pfizer Inc and is a consultant to and/or has served on advisory boards for Aclaris Therapeutics, Arena Pharmaceuticals, Concert Pharmaceuticals Inc, Dermavant Sciences, Eli Lilly and Company, and Pfizer Inc; he is on speakers bureaus for Pfizer Inc, Regeneron, and Sanofi Genzyme. The rest of the authors have no conflicts to disclose. Funding sources: Supported by a gift (to Dr King) from the Ranjini and Ajay Poddar Resource Fund for Dermatologic Diseases Research. Dr Damsky is supported by the Dermatology Foundation. Dr Meyer was supported by the Fogarty International Center/National Institutes of Health (K01TW008764-02). Conflicts of Interest: Dr Damsky has research funding from Pfizer and is a consultant for Eli Lilly. Dr Vesely's spouse works at Regeneron. Dr Choi has served on advisory boards for Merck, Pfizer, and EMD Serono. This article was prepared while Dr Meyer was employed by Yale University. The opinions expressed in this article are Dr Meyer's own and do not reflect the views of the US Army Medical Research and Material Command, the Department of the Army, the Department of Defense, or the United States Government. Dr King an investigator for Concert Pharmaceuticals Inc, Eli Lilly and Company, and Pfizer Inc and is a consultant to and/or has served on advisory boards for Aclaris Therapeutics, Arena Pharmaceuticals, Concert Pharmaceuticals Inc, Dermavant Sciences, Eli Lilly and Company, and Pfizer Inc; he is on speakers bureaus for Pfizer Inc, Regeneron, and Sanofi Genzyme. The rest of the authors have no conflicts to disclose. Funding sources: Supported by a gift (to Dr King) from the Ranjini and Ajay Poddar Resource Fund for Dermatologic Diseases Research. Dr Damsky is supported by the Dermatology Foundation . Dr Meyer was supported by the Fogarty International Center / National Institutes of Health ( K01TW008764-02 ).
Keywords
- DIHS
- DRESS
- JAK inhibitor
- Janus kinase
- acute necrotizing eosinophilic myocarditits
- drug reaction with eosinophilia and systemic symptoms
- drug-induced hypersensitivity syndrome
- tofacitinib
ASJC Scopus subject areas
- Dermatology